NanoViricides Highlights NV-387 as a Potential Solution for Ebola Outbreak

NanoViricides, Inc. stresses the urgent need for broad-spectrum antiviral treatments such as NV-387, amidst a severe Ebola outbreak in the Democratic Republic of Congo (DRC). NanoViricides claims that their oral medication could prove effective against the Bundibugyo strain, seen as a significant concern due to its spread into Uganda and high case fatality rate.

Anil R. Diwan, PhD, stated that NV-387 targets sulfated proteoglycans used by all Ebola strains for cell attachment, potentially preventing viral escape. Unlike antibodies or vaccines, NV-387 can be easily transported and administered in remote locations, with no requirement for cold chain storage.

The WHO declared the recent outbreak a Public Health Emergency, noting 88 deaths and 336 cases. The case fatality rate of ebolavirus often approaches 50%, and the virus can persist in survivors, posing a risk of re-emergence.